Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

belimumab

belimumab
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Benlysta POWDER FOR INJECTION, INTRAVENOUS 120 mg, 400 mg      
Benlysta SOLUTION, SUBCUTANEOUS 200 mg/1 mL      
Comments:

Benlysta IV medication guide

Benlysta is a new monoclonal antibody drug for treatment of systemic lupus erythematosus. The IV formulation is classified as formulary for outpatient use only. If ordered for an inpatient, it should be deferred to after discharge. Candidates for outpatient use will be evaluated on a case by case basis.

Benlysta subcutaneous is non-formulary. Inpatients may use own supply. Defer initiation to after discharge.

Reviewed: September 27, 2011 (Benlysta IV), and 12 Dec 2017 (Benlysta SubQ)

Last updated: Dec. 28, 2017






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved